We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cross Country Healthcare (CCRN - Free Report) is a Zacks Rank #2 (Buy) and it is the Bull of the Day today. This healthcare staffing firm is going to see the benefits of the rising costs in healthcare workers salaires as the pandemic rages on. There are reports that part time nurses were getting $35 per hour before the pandemic, but that level spiked to $125 and has now settled back down to $85. That is really a one off data point, but it tells the story that I want to focus on.
The idea is that healthcare workers are under phenomenial stress right now as the pandemic hs them concerned not only for patients, but themselves and the families as well. To say that they all deserve more pay is an understatement!
At the same time, there is a shortage of healthcare professionals, so this in turn will drive up the salaries that much more.
Earnings History
I see a really good earnings history with four beats in the last four quarters. There were two consecutive beats of 500%, so that has really skewed the average.
Each time the company posted those massive beats they posted and EPS gain when the consensus was calling for a loss. We have to love that!
Estimates
Wall Street has smartened up, at least for the estimates going forward. I don’t see any more losses, but still some beatable numbers. I see 7 cents for this quarter up 5 cents in the last month. Next quarter flipped from a loss of a penny to a gain of 2 cents.
The full year numbers are showing big moves, with this year moving from 12 cents to 31 cents and next year lifting from 18 cent to 29 cents.
These are solid moves in the right direction.
Valuation
The 24x forward multiple is a little high, but nothing crazy, I saw revenue contract a little in the most recent quarter but that could start to turn around. A price to book of less than 3x is great to see as value players love that and the multiple is 2x for CCRN. The price to sales multiple of 0.4x is a little worrisome, but that should resolve itself in the coming quarters.
Chart
Cross Country Healthcare, Inc. Price and Consensus
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bull Of The Day: Cross Country Healthcare (CCRN)
Cross Country Healthcare (CCRN - Free Report) is a Zacks Rank #2 (Buy) and it is the Bull of the Day today. This healthcare staffing firm is going to see the benefits of the rising costs in healthcare workers salaires as the pandemic rages on. There are reports that part time nurses were getting $35 per hour before the pandemic, but that level spiked to $125 and has now settled back down to $85. That is really a one off data point, but it tells the story that I want to focus on.
The idea is that healthcare workers are under phenomenial stress right now as the pandemic hs them concerned not only for patients, but themselves and the families as well. To say that they all deserve more pay is an understatement!
At the same time, there is a shortage of healthcare professionals, so this in turn will drive up the salaries that much more.
Earnings History
I see a really good earnings history with four beats in the last four quarters. There were two consecutive beats of 500%, so that has really skewed the average.
Each time the company posted those massive beats they posted and EPS gain when the consensus was calling for a loss. We have to love that!
Estimates
Wall Street has smartened up, at least for the estimates going forward. I don’t see any more losses, but still some beatable numbers. I see 7 cents for this quarter up 5 cents in the last month. Next quarter flipped from a loss of a penny to a gain of 2 cents.
The full year numbers are showing big moves, with this year moving from 12 cents to 31 cents and next year lifting from 18 cent to 29 cents.
These are solid moves in the right direction.
Valuation
The 24x forward multiple is a little high, but nothing crazy, I saw revenue contract a little in the most recent quarter but that could start to turn around. A price to book of less than 3x is great to see as value players love that and the multiple is 2x for CCRN. The price to sales multiple of 0.4x is a little worrisome, but that should resolve itself in the coming quarters.
Chart
Cross Country Healthcare, Inc. Price and Consensus
Cross Country Healthcare, Inc. price-consensus-chart | Cross Country Healthcare, Inc. Quote
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>